NEOS - Neos Therapeutics, Inc.
| Previous Close | 1.89 |
| Open | 1.85 |
| Bid | 1.79 x 800 |
| Ask | 1.80 x 900 |
| Day's Range | 1.77 - 1.88 |
| 52 Week Range | 1.77 - 11.69 |
| Volume | 319,602 |
| Avg. Volume | 409,944 |
| Market Cap | 87.736M |
| Beta (3Y Monthly) | 2.25 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.94 |
| Earnings Date | Nov 6, 2018 - Nov 12, 2018 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 11.83 |
- Thomson Reuters StreetEvents•3 days ago
Edited Transcript of NEOS earnings conference call or presentation 9-Nov-18 1:30pm GMT
Q3 2018 Neos Therapeutics Inc Earnings Call
- Zacks•11 days ago
Neos Therapeutics (NEOS) Reports Q3 Loss, Lags Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -7.50% and -15.52%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•11 days ago
Neos Therapeutics: 3Q Earnings Snapshot
The Grand Prairie, Texas-based company said it had a loss of 43 cents per share. The pharmaceutical company posted revenue of $12.5 million in the period. The company's shares closed at $2.58. A year ago, ...
- GlobeNewswire•11 days ago
Neos Therapeutics Reports Third Quarter 2018 Financial Results
Company to host conference call today at 8:30am ET DALLAS and FORT WORTH, Texas, Nov. 09, 2018 -- Neos Therapeutics, Inc. (Nasdaq: NEOS), a fully-integrated pharmaceutical.
- GlobeNewswire•14 days ago
Neos Therapeutics Announces Pricing of Underwritten Public Offering of $40 Million of Common Stock
DALLAS and FORT WORTH, Texas, Nov. 06, 2018 -- Neos Therapeutics, Inc. (Nasdaq:NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and.
- GlobeNewswire•15 days ago
Neos Therapeutics Announces Proposed Offering of Common Stock
Neos Therapeutics, Inc. (NEOS), a fully-integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative modified-release products using its proprietary microparticle, drug delivery technology, today announced that it has commenced an underwritten public offering of its common stock. In addition, Neos expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the offering. This offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
- GlobeNewswire•18 days ago
Neos Therapeutics to Host Third Quarter 2018 Financial Results Conference Call on November 9, 2018
DALLAS and FORT WORTH, Texas, , Nov. 02, 2018 -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will report third quarter 2018 financial results prior to the.
Market Realist•26 days agoHow Is Johnson & Johnson’s Neuroscience Business Positioned?
Johnson & Johnson’s (JNJ) neuroscience business’s revenue remained flat in the third quarter compared to the third quarter of 2017. The business’s net revenue totaled $4.58 billion in the first nine months of 2018 compared to $4.46 billion in the same period of the previous year, reflecting a ~2.6% YoY rise. In the third quarter, in the US and international markets, Johnson & Johnson’s neuroscience business generated revenues of $651.0 million and $839.0 million, respectively, compared to $647.0 million and $851.0 million, respectively, in the third quarter of 2017.
- GlobeNewswire•27 days ago
Neos Therapeutics to Present New Data for ADHD Medication, Adzenys XR-ODT®, at the American Academy of Child & Adolescent Psychiatry Meeting
DALLAS and FORT WORTH, Texas, Oct. 24, 2018 -- Neos Therapeutics, Inc. (NASDAQ: NEOS) today announced that it will present new data for Adzenys XR-ODT (amphetamine).
- GlobeNewswire•28 days ago
Neos Therapeutics Licenses Pipeline Candidate for Treatment of Sialorrhea (Excessive Drooling)
Approximately 1.4 Million Patients in the U.S. with Neurological Diseases Battle Sialorrhea with Burdensome and Complex Treatment Options Development Strategy Leverages Neos’.
- GlobeNewswire•last month
New Research Coverage Highlights Amtech, Neos Therapeutics, FTD Companies, John B. Sanfilippo & Son, Molecular Templates, and Aevi Genomic Medicine — Consolidated Revenues, Company Growth, and Expectations for 2018
NEW YORK, Oct. 16, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GlobeNewswire•2 months ago
Neos Therapeutics to Present at the Cantor Global Healthcare Conference
DALLAS and FORT WORTH, Texas, Sept. 26, 2018-- Neos Therapeutics, Inc., a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products ...
- GlobeNewswire•3 months ago
Neos Therapeutics to Present at the Wells Fargo Healthcare Conference
DALLAS and FORT WORTH, Texas, Aug. 29, 2018-- Neos Therapeutics, Inc., a fully integrated pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products ...
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of NEOS earnings conference call or presentation 8-Aug-18 12:30pm GMT
Q2 2018 Neos Therapeutics Inc Earnings Call
- Zacks•3 months ago
Neos Therapeutics (NEOS) Reports Q2 Loss, Lags Revenue Estimates
Neos Therapeutics (NEOS) delivered earnings and revenue surprises of -20.93% and -4.51%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Neos Therapeutics: 2Q Earnings Snapshot
On a per-share basis, the Grand Prairie, Texas-based company said it had a loss of 52 cents. The pharmaceutical company posted revenue of $11.4 million in the period. Neos Therapeutics shares have declined ...
- ACCESSWIRE•3 months ago
Neos Therapeutics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Neos Therapeutics, Inc. (NASDAQ: NEOS ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 8:30:00 AM Eastern ...
- TheStreet.com•5 months ago
Biotech Bargains: Two Cheap Small-Cap Stocks in an Exciting Sector
The huge American Society of Clinical Oncology or ASCO confab has called it a wrap for another year. Keytruda to treat PD-1-naive advanced melanoma patients. Dynavax's main asset for the time being is Heplisav-B, a hepatitis B vaccine approved by the FDA late in 2017.
- Simply Wall St.•6 months ago
Should You Be Concerned About Neos Therapeutics Inc’s (NASDAQ:NEOS) Shareholders?
Today, I will be analyzing Neos Therapeutics Inc’s (NASDAQ:NEOS) recent ownership structure, an important but not-so-popular subject among individual investors. Ownership structure of a company has been found to affectRead More...
